 1. Participants who had clinically significant hemorrhagic disorders e.g., hemophilia, capillary fragility, gastrointestinal ulcer, urinary tract hemorrhage, hemoptysis, and vitreous hemorrhage within 24 weeks prior to informed consent, or those who concurrently have the above disorders. 